113 related articles for article (PubMed ID: 11599800)
21. Active and inactive forms of matrix metalloproteinases 2 and 9 in cutaneous melanoma.
Candrea E; Senila S; Tatomir C; Cosgarea R
Int J Dermatol; 2014 May; 53(5):575-80. PubMed ID: 23036130
[TBL] [Abstract][Full Text] [Related]
22. Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma.
Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
Med Oncol; 2008; 25(4):431-6. PubMed ID: 18363112
[TBL] [Abstract][Full Text] [Related]
23. [Involvement of matrix metalloproteinases (MMPs) in cutaneous melanoma progression].
Ntayi C; Hornebeck W; Bernard P
Pathol Biol (Paris); 2004 Apr; 52(3):154-9. PubMed ID: 15063935
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma.
Väisänen AH; Kallioinen M; Turpeenniemi-Hujanen T
Hum Pathol; 2008 Mar; 39(3):377-85. PubMed ID: 18187184
[TBL] [Abstract][Full Text] [Related]
25. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression.
Hofmann UB; Westphal JR; Waas ET; Zendman AJ; Cornelissen IM; Ruiter DJ; van Muijen GN
Br J Cancer; 1999 Nov; 81(5):774-82. PubMed ID: 10555745
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of serum MMP-2 and MMP-7 in patients with ovarian cancer.
Acar A; Onan A; Coskun U; Uner A; Bagriacik U; Atalay F; Unsal DK; Guner H
Med Oncol; 2008; 25(3):279-83. PubMed ID: 18071928
[TBL] [Abstract][Full Text] [Related]
27. Stromal cells as the major source for matrix metalloproteinase-2 in cutaneous melanoma.
Hofmann UB; Eggert AA; Blass K; Bröcker EB; Becker JC
Arch Dermatol Res; 2005 Oct; 297(4):154-60. PubMed ID: 16047212
[TBL] [Abstract][Full Text] [Related]
28. High collagenase-1 expression correlates with a favourable chemoimmunotherapy response in human metastatic melanoma.
Nikkola J; Vihinen P; Vlaykova T; Hahka-Kemppinen M; Kähäri VM; Pyrhönen S
Melanoma Res; 2001 Apr; 11(2):157-66. PubMed ID: 11333126
[TBL] [Abstract][Full Text] [Related]
29. Identification of activated matrix metalloproteinase-2 (MMP-2) as the main gelatinolytic enzyme in malignant melanoma by in situ zymography.
Kurschat P; Wickenhauser C; Groth W; Krieg T; Mauch C
J Pathol; 2002 Jun; 197(2):179-87. PubMed ID: 12015741
[TBL] [Abstract][Full Text] [Related]
30. MT1-MMP modulates melanoma cell dissemination and metastasis through activation of MMP2 and RAC1.
Shaverdashvili K; Wong P; Ma J; Zhang K; Osman I; Bedogni B
Pigment Cell Melanoma Res; 2014 Mar; 27(2):287-96. PubMed ID: 24387669
[TBL] [Abstract][Full Text] [Related]
31. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.
Deichmann M; Benner A; Bock M; Jäckel A; Uhl K; Waldmann V; Näher H
J Clin Oncol; 1999 Jun; 17(6):1891-6. PubMed ID: 10561230
[TBL] [Abstract][Full Text] [Related]
32. Matrix metalloproteinase expression in malignant melanomas: tumor-extracellular matrix interactions in invasion and metastasis.
Bodey B; Bodey B; Siegel SE; Kaiser HE
In Vivo; 2001; 15(1):57-64. PubMed ID: 11286131
[TBL] [Abstract][Full Text] [Related]
33. Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage.
Schadendorf D; Diehl S; Zuberbier T; Schadendorf C; Henz BM
Dermatology; 1996; 192(2):89-93. PubMed ID: 8829517
[TBL] [Abstract][Full Text] [Related]
34. Invasion-associated MMP-2 and MMP-9 are up-regulated intracellularly in concert with apoptosis linked to melanoma cell detachment.
Pereira AM; Strasberg-Rieber M; Rieber M
Clin Exp Metastasis; 2005; 22(4):285-95. PubMed ID: 16170665
[TBL] [Abstract][Full Text] [Related]
35. Serum levels of matrix metalloproteinase 2 in patients with breast cancer.
Sheen-Chen SM; Chen HS; Eng HL; Sheen CC; Chen WJ
Cancer Lett; 2001 Nov; 173(1):79-82. PubMed ID: 11578812
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of heparanase and matrix metalloproteinase-9 in patients with cutaneous malignant melanoma.
Chen Y; Chen Y; Huang L; Yu J
J Dermatol; 2012 Apr; 39(4):339-43. PubMed ID: 22150440
[TBL] [Abstract][Full Text] [Related]
37. Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer.
Kanoh Y; Akahoshi T; Ohara T; Ohtani N; Mashiko T; Ohtani S; Egawa S; Baba S
Anticancer Res; 2002; 22(3):1813-7. PubMed ID: 12168874
[TBL] [Abstract][Full Text] [Related]
38. Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis.
Goldbach-Mansky R; Lee JM; Hoxworth JM; Smith D; Duray P; Schumacher RH; Yarboro CH; Klippel J; Kleiner D; El-Gabalawy HS
Arthritis Res; 2000; 2(2):145-53. PubMed ID: 11062605
[TBL] [Abstract][Full Text] [Related]
39. Membrane type-1 matrix metalloproteinase promotes human melanoma invasion and growth.
Iida J; Wilhelmson KL; Price MA; Wilson CM; Pei D; Furcht LT; McCarthy JB
J Invest Dermatol; 2004 Jan; 122(1):167-76. PubMed ID: 14962105
[TBL] [Abstract][Full Text] [Related]
40. Induction of secreted matrix metalloproteinase-9 activity in human melanoma cells by extracellular matrix proteins and cytokines.
Shellman YG; Makela M; Norris DA
Melanoma Res; 2006 Jun; 16(3):207-11. PubMed ID: 16718267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
